All In Biotech

Drug Trial Radar · NCT00445679

Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD

A Multicenter, Randomized, Double-blind, Paroxetine-referenced, Parallel-group Study to Evaluate the Safety, Efficacy, and Tolerability of 3 Fixed Doses (50mg, 100mg, AND 200mg) of Desvenlafaxine Succinate Sustained-release Tablets in Adult Outpatients With Major Depressive Disorder

Last checked: Nov 19, 2026Latest source record: Nov 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 807 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

807

Actual

Start

Jul 2007

Primary completion

Feb 2009

Study completion Feb 2009

Sponsor

Sponsor type
Industry
First posted
Mar 9, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety, tolerability and efficacy of desvenlafaxine succinate sustained release (DVS SR) in subjects with major depressive disorder.

Conditions

  • Depressive Disorder, Major

Interventions

  • DVS SRDrug

    Arm 1: 50mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 2: 100mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 3: 200mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper

  • ParoxetineDrug

    20 mg Paroxetine capsule, QD, 8 weeks treatment with 2 week taper

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Responders With a 50% or Greater Decrease From Baseline on the Hamilton Rating Scale for Depression, 17-item (HAM-D17)Time frame: 8 weeks

Locations

43 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Beijing, China

  • Site not named

    Beijing, China

  • Site not named

    Guangdong Province, China

  • Site not named

    Hunan Province, China

  • Site not named

    Jiangsu Province, China

  • Site not named

    Shanghai, China

  • Site not named

    Shanghai, China

  • Site not named

    Shanxi Province, China

  • Site not named

    Sichuan Province, China

  • Site not named

    Yunnan Province, China

  • Site not named

    Zhejiang Province, China

  • Site not named

    Andhra Pradesh, India

  • Site not named

    Andhra Pradesh, India

  • Site not named

    Andhra Pradesh, India

  • Site not named

    Andhra Pradesh, India

  • Site not named

    Chandigarh, India

  • Site not named

    Gujarat, India

  • Site not named

    Gujarat, India

  • Site not named

    Karnataka, India

  • Site not named

    Karnataka, India

  • Site not named

    Maharashtra, India

  • Site not named

    Maharashtra, India

  • Site not named

    Maharashtra, India

  • Site not named

    Mumbai Maharashtra, India

  • Site not named

    New Delhi, India

  • Site not named

    Punjab, India

  • Site not named

    Uttar Pradesh, India

  • Site not named

    Incheon, South Korea

  • Site not named

    Seoul, South Korea

  • Site not named

    Seoul, South Korea

  • Site not named

    Seoul, South Korea

  • Site not named

    Seoul, South Korea

  • Site not named

    Seoul, South Korea

  • Site not named

    Seoul, South Korea

  • Site not named

    Seoul, South Korea

  • Site not named

    Seoul, South Korea

  • Site not named

    Chang-hua, Taiwan

  • Site not named

    Kaohsiung City, Taiwan

  • Site not named

    Taipei, Taiwan

  • Site not named

    Taipei, Taiwan

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.